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Abstract
Background: Today, thrombosis is one of the most widely occurring diseases in modern life. Drugs with
thrombolytic functions are the most effective methods in the treatment of thrombosis. Among them, Douchi
fibrinolytic enzyme (DFE) is a promising agent. DFE was isolated from Douchi, a typical and popular
soybean-fermented food in China, and it can dissolve fibrin directly and efficiently. A strain, Bacillus subtilis
LD-8547 produced DFE with high fibrinolytic activity has been isolated in our lab previously.
Results: In the study, thrombolytic effect of DFE from Bacillus subtilis LD-8547 was studied in vitro and in vivo
systematically. The results showed that DFE played a significant role in thrombolysis and anticoagulation in vitro.
And the thrombolytic effects correlated with DFE in a dose-dependent manner. In vivo, the acute toxicity assay
showed that DFE had no obvious acute toxicity to mice. Test of carrageenan-induced thrombosis in mice indicated
that the DFE significantly prevented tail thrombosis, and arterial thrombosis model test indicated that Douchi
fibrinolytic enzyme DFE had thrombolytic effect on carotid thrombosis of rabbits in vivo. Other results in vivo
indicated that DFE could increase bleeding and clotting time obviously.
Conclusions: The DFE isolated from Bacillus subtilis LD-8547 has obvious thrombolytic effects in vitro and in vivo.
This function demonstrates that this enzyme can be a useful tool for preventing and treating clinical thrombus.
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Background
Nowadays, cardiovascular diseases including hyperten-
sion, coronary heart disease, atherosclerosis and acute
myocardial infarction are the leading causes of the
human death in the world. Among all kinds of cardio-
vascular diseases, thrombosis is a frequently occurred
symptom [1]. For thrombolytic therapy, the main drugs
are urokinase (UK), streptokinase (SK) and tissue plas-
minogen activator (t-PA). But they are too expensive and
their half-life is short. Besides, they are just fit for injec-
tion and have the side effect of hemorrhage. In 1897,
Nattokinase was extracted from natto [2], and it can be
absorbed by oral and injection. From then on, much
more attention was paid to the development of new
types of fibrinolytic enzyme such as enzymes isolated
from Tofuyo [3], Korean Chung kook-jang soy sauce [4],
edible honey mushroom [5], Canada blancan [6] and
Chinese Douchi [7].
Douchi fibrinolytic enzyme (DFE) is isolated from
Douchi, a typical and popular soybean-fermented food in
China, and it can dissolve fibrin directly and efficiently.
At the same time, DFE can activate t-PA in vivo. Fur-
thermore, it has no toxic and other side-effects, and will
not induce hemorrhage in vivo. The molecular weight of
DFE is low, so it not only can be absorbed directly in ali-
mentary canal, but also can be used by oral. Therefore,
the study and development of DFE have significance for
treating clinical thrombus [8,9].
A strain, Bacillus subtilis LD-8547 produced DFE with
high fibrinolytic activity has been isolated in our lab pre-
viously [10,11]. In this paper, the thrombolytic effects of
this DFE in vitro and in vivo were studied respectively.
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The agar slant medium consisted of (w/w): beef extract
0.5%, peptone l%, NaC1 0.5%, agar 1.5%, pH 7.0. The
slant was incubated at 37°C for 24 h. The flask culture
medium contained (w/w): rice power 5%, soybean power
4%, NH4NO3 0.5%, CaC12 0.01%, MgSO4 0.7%, K2HPO4
0.4%, KH2PO4 0.2%, pH 7.0 [4,12].
Purification of DFE
Bacillus subtilis LD-8547 was grown at 32°C in a
100 mL flask containing 50 mL culture medium at
150 r/min for 72 h. DFE was purified by a previously
described method of Wang et al. [13] with a series of
procedure including salt-out, dialysis and gel filtration
chromatography with Sephadex G-100.
Fibrinolytic activity assay
Amidolytic activity of the DFE was estimated using syn-
thetic substrate (Suc-Ala-Ala-Pro-Phe-pNA) [7]. The re-
action mixture containing 8 μL of 1 mM synthetic
substrate, 40 μL of 20 mM Tris–HCl buffer (pH 8.0) and
6 μL of enzyme solution was incubated at 37°C for
10 min. The absorbance of released pNA at 405 nm was
measured with a microplater. One unit of the amidolytic
activity was defined as the amount of enzyme that liber-
ated 1 ng of p-nitroanilide per minute. Protein was
determined using Folin Ciocalteau phenol reagent.
Thrombolytic effects of DFE in vitro
Anticoagulant effect of DFE on animal blood
Fresh animal blood samples (rat, rabbit and sheep) were
collected, and different doses of DFE (2070 U, 1035 U,
518 U and 259 U) were added into these samples, re-
spectively. The control was added with 1 mL Tris–HCl.
After mixed gently, the mixture was incubated at 37°C
for 30 min. Then the anticoagulant effects of DFE on
animal blood were observed.
Clot lytic effect of DFE
Clot lytic effect of DFE was studied with natural clot
in vitro. The animal blood clot was cut into the same
size, and 5000 U urokinase (as a positive control), Tris–
HCl buffer (as a negative control) and different doses
(414 U, 621 U, 1035 U and 2070 U) of DFE were added.
The mixture was incubated at 37°C for 24 h. Then ali-
quots were taken from the reaction mixture for analysis
[14].
Euglobulin lysis experiment
According to Cheng and Buckell [15,16], 0.5 mL plasma
was added into in a centrifuge tube containing 9 mL dis-
tilled water. The pH was adjusted to 4.5 by adding
0.1 mL of 1% acetic acid. The mixture was placed at 4°C
for 10 min. After euglobulin fraction of the plasma was
precipitated, the tubes were centrifuged at 3000 r/min
for 5 min. The supernatant was decanted, and 0.5 mL
borate solution (pH 9.0) was added to the precipitate.
The mixture was placed at 37°C for 2 min and stirred
gently with a glass rod. Also, 0.5 mL of 0.025 M calcium
chloride solution was added to form euglobulin clots.
Then DFE was added to the clots at different doses (469
U, 938 U and 1877 U). The tubes were incubated at
37°C, and the lysis of clots was inspected after 2.5 h.
The hemolysis test of blood erythrocytes
Red blood cell suspension (2%) was prepared according to
Chinese Pharmacopoeia (2010 edition) [17]. And different
doses (207 U, 414 U, 621 U, 828 U and 1035 U) of DFE
were added into it respectively. Normal saline (NS) and dis-
tilled water were added as controls. After mixed gently, the
mixture was incubated at 37°C. After 6 h, the absorbance of
supernatant was determined at 545 nm by spectrophotom-
eter with distilled water as a blank control. Hemolysis
effect was determined by the formula as following:
hemolysis rate %ð Þ ¼ ODtODncð Þ= ODpcODncð Þ
 100%:
ODt was tested absorbance. ODnc was negative absorb-
ance. ODpc was positive absorbance. If hemolysis rate
exceeds 5%, it demonstrates that the DFE dose is not suit-
able for injection.
Thrombolytic effects of DFE in vivo
Acute toxicity assay
Kunming mice and New Zealand rabbits used for animal
experiment were purchased from the Shanghai Labora-
tory Animal Center, and all animal work was performed
according to relevant national and international guide-
lines. All animal experiments were approved by the Ani-
mal Ethics Committee of the Fujian Agriculture and
Forestry University. In order to evaluate the acute tox-
icity of DFE on adult mice,tests were carried out accord-
ing to the method described by Wang [11]. Twenty
female and twenty male mice (20 ± 2 g) were housed in
stainless steel cages in a ventilated animal room. Dis-
tilled water and sterilized food for mice were available
ad libitum.
They were acclimated to this environment for 7 days
prior to dosing. Mice were randomly divided into four
groups: control groups (female and male) and experi-
mental groups (female and male). Before treatment, mice
were fasted overnight. Subsequently, the control groups
and the experimental groups were given NS and DFE re-
spectively by mouth, and then were provided with food
and water 2 h later. The symptom and mortality were
observed and recorded carefully in 2 weeks.
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Thrombolytic effect of DFE on mouse thrombosis model
Male Kunming mice were randomly divided into 4
groups. Group 1 served as control was treated with NS.
Groups 2, 3, 4 were given 2051, 4103 and 8206 U/35 g
bw (body weight) purified DFE dissolved in NS by oral
administration for a week, respectively. Half an hour
after the last treatment with the DFE, 17 μL/10 g bw
carrageenan were injected through celiac. The thrombus
lengths were measured at 24 h. Each experiment was
done at a minimum in triplicate [18].
Effect of DFE on bleeding and clotting time
Mice were divided into four groups randomly (five mice
were used per group) and treated with NS and different
doses of DFE (2206 U, 4412 U and 8824 U) by mouth
for a week respectively. The bleeding time was measured
by using a standard incision in the tail of mice. Mice
were fixed, and then 3 mm tail tips were cut. When the
tail was bleeding, the blood was wiped every 30 s. The
bleeding time was measured until bleeding stopped
naturally.
The clotting time was determined using the method
previously described [19]. An hour after the last treat-
ment with different doses of DFE, a drop of blood was
put on the clean slide. Then the blood was stirred by dry
pinhead every 30 s. The clotting time was measured
until fibrin filament was stir out.
Lytic effect of DFE on whole blood clot and plasma clot
Mice were divided into four groups randomly (five mice
were used per group) and treated with NS and different
doses of DFE (4100,8200,16400 U/35 g bw) by oral for a
week respectively. Half an hour after the last treatment,
1 mL blood was collected from eyes. The blood was
incubated at 37°C until it was clotted. Then the lysis of
blood clots was observed after 4 h.
Plasma clots were prepared as followed: the blood
(1 mL) were added with sodium citrate (0.2 mL, 3.8%)
and then centrifuged at 3000 r/min for 10 min. Plasma
was separated (0.4 mL) and incubated at 37°C adding
with 8 U of thrombin to form clot. The lytic effect of
DFE on plasma clots was observed after 3 h.
Effect of DFE on carotid artery thrombosis
Ten New Zealand rabbits were divided into two groups:
control group and DFE group. DFE group were fixed
and their carotid arteries were exposed after anesthetiz-
ing by 20% urethane (5 mg/kg). And then, thrombosis
was formed by covering a piece of filter paper
(1.0 cm× 1.5 cm, with 10% FeCl3) on the carotid artery
for 15 min. At the same time, the rabbits were treated
with DFE (1035 U/kg) by abdominal injection. The effect
of DFE on the carotid thrombosis was observed at differ-
ent time [20].
Results
Purification of DFE and fibrinolytic activity assay
DFE was purified from Bacillus subtilis LD-8547 with a
series of procedures. The activity of DFE was estimated
with synthetic substrate. And the results showed that
the fibrinolytic activity of DFE reached 21750 U/mL
after condensed (Figure 1).
Thrombolytic effects of DFE in vitro
Anticoagulant effect of DFE on animal blood
The anticoagulant effects of DFE on animal blood were
tested. The results indicated that low dose DFE (259 U)
had no notable effect on clot of rabbit blood, but anti-
coagulant effect was gradually enhanced with the increas-
ing dose of DFE (Figure 2A). With 518 U and 1035 U of
DFE, the bloods were coagulated partly. And anticoagu-
lant effect was very obvious when DFE concentration
reached 2070 U. The blood was fluid and not clotted.
Anticoagulant effects of DFE on other animal blood
such as rat and sheep were similar to that of rabbit
blood (Figure 2B, 2C).
Clot lytic effect of DFE
Solubility rate of blood clots were detected by adding dif-
ferent doses of DFE to prepared rabbit blood clots. And
the results showed that DFE lysed the clots with solubility
rate of 73%, 83%, 91% and 98%, respectively, compared
with 83% of UK and 5% of negative control (Figure 3A).
The clot lytic effect on other blood clots of rat, pig,
sheep, cattle and human was similar to that of rabbit
blood (Figure 3B). These results suggested that DFE had
obvious effect on dissolving the blood clot, and the effect
was enhanced as the concentration of DFE increased.
Euglobulin lysis experiment
The lysis effect of DFE on euglobulin was determined by
weighing the wet weight of the residual euglobulin clots










Figure 1 SDS-PAGE assay of DFE protein. M: Protein Marker; Lane
1: DFE Unpurified by Sephadex G-100; Lane 2: Purified DFE by
Sephadex G-100.
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after treated with DFE. The results showed that low dose
DFE (469 U) could dissolve part of the clot (38.4%), and
higher dose DFE (938 U and 1877 U) lysed almost all
the euglobulin clots (96.6% and 99.3%) after 2.5 h treat-
ment (Figure 4A, 4B).
The hemolysis test of blood erythrocytes
Different doses of DFE were added to erythrocytes and
then hemolysis rate was tested. The results indicated
that there were no obvious hemolysis and agglutination
effects on rabbit erythrocytes (Figure 5A). Hemolysis
rates of high dose DFE (828 U and 1035 U) were a little
more than 5% (5.35% and 6.33%, respectively), but low
dose DFE (207 U, 414 U and 621 U) did not hemolyze
erythrocytes obviously, and their hemolysis rates were
less than 5% (Figure 5B). So they were safe and fit for
intravenous injection.
The haemolytic effect of DFE on rat, pig, sheep, cattle
and human blood erythrocytes was similar to that of
rabbit blood on the whole (Figure 6).
A 1 2 3 4 5 B1 2 3 4 5 C 1 2 3 4 5
Figure 2 Anticoagulant effect of DFE with different concentrations on animal bloods in vitro. A-C was rabbit blood, rat blood and sheep
































































Figure 3 Thrombolytic effects of different doses of DFE on animal blood clot in vitro. A: The solubility rate of rabbit’s blood clot after
treated with DFE (414 U, 621 U, 1035 U and 2070 U) and UK (5000 U). B: The solubility rate of different animal blood clots after treated with DFE
(414 U, 621 U, 1035 U and 2070 U) and UK (5000 U). UK: urokinase.
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Thrombolytic effects of DFE in vivo
Acute toxicity assay
The mice were given 691,586 U/Kg DFE for 2 weeks,
and then the weight of mice body and various organs
were detected. As a result, DFE showed no obvious
acute toxicity to mice. Morphology of mice viscera given
with DFE were nearly the same to the control, and there
were no abnormal changes of the pathologic section in
the hearts, livers, spleens, lungs, kidneys, stomachs and
intestines of all mice (Figure 7A). Also, no obvious dif-
ferences were found in the body weight and viscera
(P >0.05) (Figure 7B-7D).
Thrombolytic effect of DFE on mouse thrombus model
In order to detect the thrombolytic effect of DFE in vivo,
Carrageenan-induced tail thrombus model was used. Tail
thrombus was formed at 24 h after the injection of car-
rageenan (Figure 8A). After treated with different dose
DFE according to Methods, mice were subcutaneously
injected with carrageenan, and then length of tail
thrombus was measured at 24 h. It was showed that
DFE could significantly inhibit thrombus formation in
carrageenan-induced thrombosis model in mice
(Figure 8B-8D). The average thrombus length in group 1
was 3.7 cm, and the average length of thrombus
decreased sharply in groups 2 (2 cm) and 3 (0.4 cm), re-
spectively, with the increasing amount of DFE. The
thrombus nearly disappeared in the tip of mouse tail in
group 4(Figure 8E). The results suggested that DFE can
prevent tail thrombosis induced by carrageenan, and the
effect was enhanced with the increasing dose of DFE.
Effect of DFE on bleeding and clotting time
In vivo assay, it showed that the enzyme could affect
both the bleeding and clotting time of experimental























A 1 2 3 4 B
Figure 4 The euglobulin lysis by DFE. A: 1–3: Euglobulin added with DFE of 1877 U, 938 U and 469 U respectively; 4: Control group adding
with Tris–HCl. B: The weight of the rest fibrin clot after treated with Tris–HCl and different dose of DFE (469 U, 938 U and 1877 U).































Figure 5 The hemolysis test on blood erythrocytes of rabbit. A: Rabbit erythrocyte added with different agent. 1–5: Rabbit erythrocyte
added with 207 U, 414 U, 621 U, 828 U and 1035 U of DFE, respectively. 6: NS; 7: Distilled water; B: The hemolysis rate of rabbit erythrocytes
added with DFE.
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time and the dose of DFE. The bleeding and clotting
time were postponed obviously when treated with high
dose of DFE (p< 0.05). Also low dose and middle dose
of DFE could postpone the time, but had no marked ef-
fect compared to the control group (Figure 9A, 9B).
Lytic effect of DFE on whole blood clot and plasma clot
The results (Figure 10A) showed that the enzyme could
lyse whole blood clot as well as plasma clot within
30 min. There was a dose-dependency relationship be-
tween DFE and solubility of blood clots. The higher dose
(8200 U and 16400 U) of DFE could increase the solubil-
ity of blood clots markedly (p< 0.05), but the low dose
(4100 U) of DFE had no obvious effect (P> 0.05). Also,
lytic activity of DFE to plasma clot became higher as the
dose increasing. Compared to the control, plasma clots
could be lysed obviously even with low dose of DFE















































Human blood erythrocytes 





























































































Figure 7 The acute toxicity test of DFE. A: the morphology of mice viscera after given DFE for two weeks. B: the weight of male mice. C: the
weight of female mice. D: Ratio of viscera to body weight.
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Arterial thrombosis model
To assess the thrombolytic effect of DFE in vivo, FeCl3
was applied to the exposed carotid artery to elicit an
endothelial damage. Before thrombus was made, vessel
was bright red and the blood flowed normally
(Figure 11A). After the formation of thrombus, vascular
wall turned dark obviously, the vessel contracted and
blood flowed slowly (Figure 11B). Meanwhile, the results
demonstrated that although the thrombus formed vessel
wall was a bit darker than normal vessel 2 d after DFE
injection, the thrombus formed vessel became bright red
and the blood flowed normally again (Figure 11C). It
suggested that DFE had favorable thrombolytic effect
in vivo.
Discussion
In recent years, in order to enhance the efficacy and
safety of fibrinolytic therapy, many researches were pur-
sued to discover fibrinolytic enzymes from food-grade
microorganisms. Among them, much attention was paid
to fibrinolytic enzymes isolated from Douchi.
In this study, many experiments were carried out to test
the thrombolytic effect of Douchi fibrinolytic enzyme from
Bacillus subtilis LD-8547 in vitro and in vivo. The assay
demonstrated that in the groups treated with more than
518 U of DFE, the anticoagulation effect was obvious on
animal blood, and the effect was enhanced with increasing
dose of DFE. The cascade and waterfall hypotheses of
blood coagulation indicate that the coagulation process is
divided into three stages: the formation of prothrombin
activator, thrombin formation and fibrin formation. In this
study, the result indicated that DFE can inhibit the extrin-
sic coagulation system, which may be the key to antith-
rombotic and thrombolytic activity. And in the low dose
group (259 U), there is no or fewer side effects in bleeding
and does not affect the body's normal clotting mechanism.
Therefore, low dose DFE is recommended for the long-































Figure 8 Thrombolytic effect of DFE on tail thrombus model caused by carrageenan. A: Tail thrombus model. B-D: The morphology of
mice tail after given DFE for 24 h (2051 U/35 g bw, 4103 U/35 g bw , 8206 U/35 g bw). E: The length of mice tail thrombus after injecting DFE.
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Antithrombotic or thrombolytic drugs can block the
pathway of thrombus formation. The fundamental task
of thrombolytic therapy is the degradation of fibrin by
plasmin, which can be activated by the activators from
inactive plasminogen. SK and UK depend on this indir-
ect activation pathway. In addition to this indirect work-
ing mechanism, thrombolytic enzyme can dissolve fibrin
directly, which was proved by our thrombolysis experi-
ments in vitro. Our studies demonstrated that DFE
displayed strong thrombolytic ability in mouse. Its effect
is better than clinically used UK.
Thrombus formed via the effects of cruor, anticoagula-
tion, fibrinolytic system, haemorheology, vascular endo-
thelial cells, platelets and other factors. Animal
thrombosis models are the most effective way to evalu-
ate the function of thrombolytic agents. As an experi-
mental model of peripheral obstructive disease,
carrageenan-induced thrombosis in mice was used, be-
cause of its advantages of simple induction in small la-
boratory animals and easy to observe without killing the
animals. In this study, the results showed that DFE sig-
nificantly inhibited tail thrombus formation after the in-
jection of carrageenan. The antithrombotic effect of DFE
is even more obvious than some newly reported fibrino-
lytic enzymes such as Subtilisin QK [16].
The oxidative damage of the endarterium induced by
FeCl3 is the traditional method to establish the Animal
Blood Bolts Model, and it is convenient, fast and the
results are reproducible. A moderate concentration
(10%) of FeCl3 was used in this study, and the fibrino-
lytic system could dissolve fibrin, which is the main
component of thrombus. The impacts on the fibrinolytic
system are the key to evaluate the effect of thrombolytic
drugs. In the study, markedly thrombolytic effect of DFE
was showed in the in vivo test after the carotid artery
thrombosis was made.
Microorganism is an important source of thrombolytic
enzymes. With the fast growth and easy control charac-
teristics, microorganism can be manually controlled to
obtain the target product. With the development of fer-
mentation industry and extraction of fermentation pro-
ducts, there will be a broad prospect of clinical use of
this thrombolytic agent.
Many factors play important roles in thrombosis. Mo-
lecular mechanisms on effective prevention and treat-
ment of thrombosis of the DFE from Bacillus subtilis
LD-8547 is not clear now. Therefore, a further study is
needed in the future.
Conclusions
The present results extend our previous findings that
the DFE from Bacillus subtilis LD-8547 has effective fi-
brinolytic activity on fibrin plates and plasma plates. In
addition, in this work, we found that DFE could lyse
euglobulin, relieve thrombus symptom on tail of mouse
and carotid of rabbit, elongate bleeding and clotting
time, and also had an anticoagulant and clot lytic effect
on animal blood. Simultaneously, no toxicity to the mice
and no perniciasm on erythrocytes were detected.
Therefore, taken together the results clearly illustrate
that the DFE has promises in clinical applications to pre-

















































































Figure 10 Lysis of the whole blood clot and plasma clot. A: the
weight of solute blood clot after mice were treated with different
dose of DFE (4100 U, 8200 U and 16400 U); B: the weights of
undissolved plasma clot after mice were treated with different dose























































Figure 9 Bleeding time (A) and clotting time (B) of mice treated
with DFE (2206U, 4412U and 8824U).
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Figure 11 Arterial thrombosis model test of DFE. A: Natural carotid arteries. B: Arterial thrombosis model made by FeCl3. C: Carotid arteries
after thrombosis model were injected with DFE (1035 U/kg) for 2 days.
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